EUVIMEDEUVIMED entdecken
Crossref

Hyperthyroidism Can Precipitate Peak‐Dose Levodopa‐Induced Dyskinesia in Parkinson's Disease

Soutarou Taguchi iD, Hiroyuki Suzuki, Takahiro Nakura, Naoki Atsuta, Hidemoto Saiki

Movement Disorders Clinical Practice · 2026-06 · 13 (6) · 1560-1562

DOI: 10.1002/mdc3.70496 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Movement Disorders Clinical Practice, online erschienen am 30.12.2025. Verfasst von Soutarou Taguchi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Parkinson's Disease Advanced Therapy Center, Aichi Medical University Hospital, Nagakute, Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 5 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ethical Compliance Statement: This study did not require approval by an institutional review board, as it describes a single clinical case and was conducted in accordance with the principles of the Declaration of Helsinki. Verbal and written informed consent were obtained from the patient for publication of this case study and the accompanying video material. The consent form explicitly stated that the patient understood that their medical information and still or video images related to the conditions of hyperthyroidism, Parkinson's disease, and dyskinesia might be published in academic journals, including online access, and could be viewed by healthcare professionals and the general public. The patient also understood that all personally identifiable information would be removed and that the consent could be withdrawn at any time. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this work is consistent with those guidelines. Funding Sources and Conflict of Interest: No specific funding was received for this work and the authors declare that there are no conflicts of interest relevant to this work. Financial Disclosures for the previous 12 months: ST has received honoraria and travel expenses from AbbVie GK. for speaking at meetings, and grants from PDR Pharma Inc. NA has received honoraria for lecturing from Mitsubishi Tanabe Pharma, Biogen, Eisai, Alexion, Eli Lilly, Kowa, Novartis, and Argenx, as well as research grants from the Japan Agency for Medical Research and Development (AMED) and the Grants-in-Aid for Scientific Research. He has also served as a consultant for Ono Pharma and Biogen. HS has received honoraria and travel expenses from Kyowa Kirin Co., Ltd., Eisai Co., Ltd., Sumitomo Pharma Co., Ltd., Medtronic Japan Co., Ltd., Ono Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Taiyo Pharma Co., Ltd., AbbVie GK., InSightec Japan Co., Ltd., and consultation fee from e-Projection K.K. The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

Autor:innen und Institutionen

  • Parkinson's Disease Advanced Therapy Center, Aichi Medical University Hospital, Nagakute, Japan.
  • Department of Neurology, Aichi Medical University, Nagakute, Japan.

ORCID-Profile: Soutarou Taguchi

Zitieren

APA

Taguchi, S., Suzuki, H., Nakura, T., Atsuta, N., & Saiki, H. (2026). Hyperthyroidism Can Precipitate Peak‐Dose Levodopa‐Induced Dyskinesia in Parkinson's Disease. Movement Disorders Clinical Practice, 13(6), 1560-1562. https://doi.org/10.1002/mdc3.70496

Vancouver

Taguchi S, Suzuki H, Nakura T, Atsuta N, Saiki H. Hyperthyroidism Can Precipitate Peak‐Dose Levodopa‐Induced Dyskinesia in Parkinson's Disease. Movement Disorders Clinical Practice. 2026;13(6):1560-1562. doi:10.1002/mdc3.70496

BibTeX
@article{Taguchi2026,
  author = {Taguchi, Soutarou and Suzuki, Hiroyuki and Nakura, Takahiro and Atsuta, Naoki and Saiki, Hidemoto},
  title = {Hyperthyroidism Can Precipitate Peak‐Dose Levodopa‐Induced Dyskinesia in Parkinson's Disease},
  journal = {Movement Disorders Clinical Practice},
  year = {2026},
  volume = {13},
  number = {6},
  pages = {1560--1562},
  doi = {10.1002/mdc3.70496}
}
Kostenlos starten →